Pharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients.

@article{Turner2013PharmacoeconomicsOE,
  title={Pharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients.},
  author={Stuart J. Turner and Sharon C. A. Chen and Monica A. Slavin and David C. M. Kong},
  journal={Expert review of pharmacoeconomics & outcomes research},
  year={2013},
  volume={13 2},
  pages={227-35}
}
Invasive fungal infections incur considerable costs to healthcare and are associated with high mortality. These infections are increasing, due in part to more intensive immunosuppressive regimens with longer periods of neutropenia for patients treated for conditions such as cancer and hematopoietic stem cell transplantation. Therapeutic strategies in treating invasive fungal infections include the initiation of empiric antifungal therapy. This early treatment is triggered by fever that is… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-6 of 6 extracted citations

Preemptive Antifungal Therapy for Febrile Neutropenic Hematological Malignancy Patients in China

Medical science monitor : international medical journal of experimental and clinical research • 2016
View 2 Excerpts

Similar Papers

Loading similar papers…